View Financial HealthQuest Laboratories 배당 및 자사주 매입배당 기준 점검 0/6Quest Laboratories 배당금을 지급한 기록이 없습니다.핵심 정보n/a배당 수익률0%자사주 매입 수익률총 주주 수익률0%미래 배당 수익률n/a배당 성장률n/a다음 배당 지급일n/a배당락일n/a주당 배당금n/a배당 성향n/a최근 배당 및 자사주 매입 업데이트업데이트 없음모든 업데이트 보기Recent updatesValuation Update With 7 Day Price Move • Jun 17Investor sentiment improves as stock rises 16%After last week's 16% share price gain to ₹116, the stock trades at a trailing P/E ratio of 8.9x. Average trailing P/E is 29x in the Pharmaceuticals industry in India. Total returns to shareholders of 26% over the past year.Valuation Update With 7 Day Price Move • Jun 02Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to ₹101, the stock trades at a trailing P/E ratio of 7.7x. Average trailing P/E is 29x in the Pharmaceuticals industry in India. Total returns to shareholders of 24% over the past year.분석 기사 • Jun 02Here's Why We Think Quest Laboratories (NSE:QUESTLAB) Is Well Worth WatchingIt's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...공고 • May 27Quest Laboratories Limited to Report Q4, 2026 Results on May 29, 2026Quest Laboratories Limited announced that they will report Q4, 2026 results on May 29, 2026New Risk • May 08New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Indian stocks, typically moving 10% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (10% average weekly change). Minor Risk Market cap is less than US$100m (₹2.13b market cap, or US$22.5m).Valuation Update With 7 Day Price Move • May 01Investor sentiment improves as stock rises 21%After last week's 21% share price gain to ₹152, the stock trades at a trailing P/E ratio of 11.6x. Average trailing P/E is 29x in the Pharmaceuticals industry in India. Total returns to shareholders of 41% over the past year.Valuation Update With 7 Day Price Move • Apr 17Investor sentiment improves as stock rises 21%After last week's 21% share price gain to ₹127, the stock trades at a trailing P/E ratio of 9.7x. Average trailing P/E is 28x in the Pharmaceuticals industry in India. Total returns to shareholders of 8.5% over the past year.Valuation Update With 7 Day Price Move • Mar 04Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to ₹110, the stock trades at a trailing P/E ratio of 8.4x. Average trailing P/E is 26x in the Pharmaceuticals industry in India. Total loss to shareholders of 12% over the past year.Reported Earnings • Feb 16Third quarter 2026 earnings released: EPS: ₹2.46 (vs ₹1.70 in 3Q 2025)Third quarter 2026 results: EPS: ₹2.46 (up from ₹1.70 in 3Q 2025). Revenue: ₹311.8m (up 1.7% from 3Q 2025). Net income: ₹40.3m (up 45% from 3Q 2025). Profit margin: 13% (up from 9.1% in 3Q 2025). The increase in margin was primarily driven by lower expenses.분석 기사 • Feb 12Does Quest Laboratories (NSE:QUESTLAB) Have A Healthy Balance Sheet?Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...New Risk • Feb 11New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Indian stocks, typically moving 9.6% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (9.6% average weekly change). High level of non-cash earnings (33% accrual ratio). Minor Risk Market cap is less than US$100m (₹2.12b market cap, or US$23.4m).Valuation Update With 7 Day Price Move • Feb 11Investor sentiment improves as stock rises 28%After last week's 28% share price gain to ₹129, the stock trades at a trailing P/E ratio of 14.9x. Average trailing P/E is 28x in the Pharmaceuticals industry in India. Total loss to shareholders of 17% over the past year.공고 • Feb 06Quest Laboratories Limited to Report Q3, 2026 Results on Feb 13, 2026Quest Laboratories Limited announced that they will report Q3, 2026 results on Feb 13, 2026New Risk • Dec 25New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 6.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (33% accrual ratio). Minor Risks Share price has been volatile over the past 3 months (6.9% average weekly change). Market cap is less than US$100m (₹1.60b market cap, or US$17.8m).Valuation Update With 7 Day Price Move • Dec 19Investor sentiment improves as stock rises 24%After last week's 24% share price gain to ₹109, the stock trades at a trailing P/E ratio of 12.5x. Average trailing P/E is 28x in the Pharmaceuticals industry in India. Total loss to shareholders of 1.1% over the past year.분석 기사 • Nov 21Concerns Surrounding Quest Laboratories' (NSE:QUESTLAB) PerformanceQuest Laboratories Limited's ( NSE:QUESTLAB ) healthy profit numbers didn't contain any surprises for investors. We...공고 • Nov 13Quest Laboratories Limited to Report First Half, 2026 Results on Nov 13, 2025Quest Laboratories Limited announced that they will report first half, 2026 results on Nov 13, 2025공고 • Sep 04Quest Laboratories Limited, Annual General Meeting, Sep 29, 2025Quest Laboratories Limited, Annual General Meeting, Sep 29, 2025, at 12:30 Indian Standard Time.Reported Earnings • Jul 26First quarter 2026 earnings released: EPS: ₹2.50 (vs ₹0.90 in 1Q 2025)First quarter 2026 results: EPS: ₹2.50 (up from ₹0.90 in 1Q 2025). Revenue: ₹231.8m (up 52% from 1Q 2025). Net income: ₹41.0m (up 178% from 1Q 2025). Profit margin: 18% (up from 9.7% in 1Q 2025). The increase in margin was driven by higher revenue.분석 기사 • Jul 26A Piece Of The Puzzle Missing From Quest Laboratories Limited's (NSE:QUESTLAB) 28% Share Price ClimbQuest Laboratories Limited ( NSE:QUESTLAB ) shares have had a really impressive month, gaining 28% after a shaky period...Valuation Update With 7 Day Price Move • Jul 23Investor sentiment improves as stock rises 16%After last week's 16% share price gain to ₹108, the stock trades at a trailing P/E ratio of 13x. Average trailing P/E is 33x in the Pharmaceuticals industry in India. Total loss to shareholders of 25% over the past year.New Risk • Jun 30New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Indian stocks, typically moving 9.1% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (9.1% average weekly change). High level of non-cash earnings (29% accrual ratio). Minor Risks Latest financial reports are more than 6 months old (reported September 2024 fiscal period end). Market cap is less than US$100m (₹1.54b market cap, or US$18.0m).New Risk • Jun 02New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended September 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (29% accrual ratio). Minor Risks Latest financial reports are more than 6 months old (reported September 2024 fiscal period end). Share price has been volatile over the past 3 months (8.5% average weekly change). Market cap is less than US$100m (₹1.43b market cap, or US$16.8m).New Risk • May 29New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 6.1% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (29% accrual ratio). Minor Risks Share price has been volatile over the past 3 months (6.1% average weekly change). Market cap is less than US$100m (₹1.71b market cap, or US$20.0m).Valuation Update With 7 Day Price Move • May 29Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to ₹83.75, the stock trades at a trailing P/E ratio of 11.6x. Average trailing P/E is 33x in the Pharmaceuticals industry in India. Total loss to shareholders of 34% over the past year.Board Change • May 14Less than half of directors are independentThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, 3 were independent directors. The company's board is composed of: 3 independent directors. 4 non-independent directors. Non-Executive Independent Director Gautam Kothari was the last independent director to join the board, commencing their role in 2024. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity.Valuation Update With 7 Day Price Move • Apr 03Investor sentiment improves as stock rises 17%After last week's 17% share price gain to ₹115, the stock trades at a trailing P/E ratio of 16x. Average trailing P/E is 29x in the Pharmaceuticals industry in India.Board Change • Mar 06Less than half of directors are independentThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, 3 were independent directors. The company's board is composed of: 3 independent directors. 4 non-independent directors. Non-Executive Independent Director Gautam Kothari was the last independent director to join the board, commencing their role in 2024. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity.Valuation Update With 7 Day Price Move • Jan 22Investor sentiment improves as stock rises 16%After last week's 16% share price gain to ₹150, the stock trades at a trailing P/E ratio of 20.8x. Average trailing P/E is 33x in the Pharmaceuticals industry in India.Recent Insider Transactions • Jan 21Chairman & MD recently bought ₹1.2m worth of stockOn the 15th of January, Anil Sabarwal bought around 10k shares on-market at roughly ₹130 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. In the last 3 months, they made an even bigger purchase worth ₹4.2m. Anil has been a buyer over the last 12 months, purchasing a net total of ₹6.7m worth in shares.Recent Insider Transactions • Jan 07Chairman & MD recently bought ₹4.2m worth of stockOn the 2nd of January, Anil Sabarwal bought around 34k shares on-market at roughly ₹125 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. This was Anil's only on-market trade for the last 12 months.Valuation Update With 7 Day Price Move • Jan 02Investor sentiment improves as stock rises 17%After last week's 17% share price gain to ₹128, the stock trades at a trailing P/E ratio of 17.8x. Average trailing P/E is 37x in the Pharmaceuticals industry in India.분석 기사 • Nov 22Quest Laboratories' (NSE:QUESTLAB) Solid Profits Have Weak FundamentalsQuest Laboratories Limited's ( NSE:QUESTLAB ) stock was strong after they recently reported robust earnings. However...Reported Earnings • Nov 16First half 2025 earnings released: EPS: ₹4.89 (vs ₹4.42 in 1H 2024)First half 2025 results: EPS: ₹4.89 (up from ₹4.42 in 1H 2024). Revenue: ₹434.6m (up 6.0% from 1H 2024). Net income: ₹80.1m (up 46% from 1H 2024). Profit margin: 18% (up from 13% in 1H 2024).Valuation Update With 7 Day Price Move • Oct 23Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to ₹91.50, the stock trades at a trailing P/E ratio of 14.9x. Average trailing P/E is 38x in the Pharmaceuticals industry in India.분석 기사 • Oct 22Not Many Are Piling Into Quest Laboratories Limited (NSE:QUESTLAB) Just YetQuest Laboratories Limited's ( NSE:QUESTLAB ) price-to-earnings (or "P/E") ratio of 15.7x might make it look like a...Board Change • Sep 17Less than half of directors are independentFollowing the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 4 non-independent directors. Non-Executive Independent Director Gautam Kothari was the last independent director to join the board, commencing their role in 2024. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.공고 • Sep 06Quest Laboratories Limited Appoints Executive DirectorsQuest Laboratories Limited at the AGM held on September 4, 2024 approved the regularisation of additional director Mr. Vinayak Sabarwal and Mr. Umendra Singh by appointing them as Executive Directors of the Company.공고 • Aug 12Quest Laboratories Limited, Annual General Meeting, Sep 04, 2024Quest Laboratories Limited, Annual General Meeting, Sep 04, 2024, at 16:30 Indian Standard Time.Valuation Update With 7 Day Price Move • Jun 11Investor sentiment improves as stock rises 18%After last week's 18% share price gain to ₹128, the stock trades at a trailing P/E ratio of 41.6x. Average trailing P/E is 33x in the Pharmaceuticals industry in India.지급의 안정성과 성장배당 데이터 가져오는 중안정적인 배당: 과거에 QUESTLAB 의 주당 배당금이 안정적이었는지 판단하기에는 데이터가 부족합니다.배당금 증가: QUESTLAB 의 배당금 지급이 증가했는지 판단하기에는 데이터가 부족합니다.배당 수익률 vs 시장Quest Laboratories 배당 수익률 vs 시장QUESTLAB의 배당 수익률은 시장과 어떻게 비교되나요?구분배당 수익률회사 (QUESTLAB)n/a시장 하위 25% (IN)0.3%시장 상위 25% (IN)1.5%업계 평균 (Pharmaceuticals)0.7%분석가 예측 (QUESTLAB) (최대 3년)n/a주목할만한 배당금: 회사가 최근 지급을 보고하지 않았기 때문에 하위 25%의 배당금 지급자에 대해 QUESTLAB 의 배당 수익률을 평가할 수 없습니다.고배당: 회사가 최근 지급을 보고하지 않았기 때문에 배당금 지급자의 상위 25%에 대해 QUESTLAB 의 배당 수익률을 평가할 수 없습니다.주주 대상 이익 배당수익 보장: 배당금 지급이 수익으로 충당되는지 확인하기 위해 QUESTLAB 의 지급 비율을 계산하기에는 데이터가 부족합니다.주주 현금 배당현금 흐름 범위: QUESTLAB 에서 지급을 보고하지 않았기 때문에 배당 지속 가능성을 계산할 수 없습니다.높은 배당을 제공하는 우량 기업 찾기7D1Y7D1Y7D1YIN 시장에서 배당이 강한 기업.View Management기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/08/17 04:20종가2026/08/17 00:00수익2025/12/31연간 수익2025/03/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 GitHub 페이지에서 확인하실 수 있습니다. 또한 보고서 사용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Quest Laboratories Limited는 0명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
Valuation Update With 7 Day Price Move • Jun 17Investor sentiment improves as stock rises 16%After last week's 16% share price gain to ₹116, the stock trades at a trailing P/E ratio of 8.9x. Average trailing P/E is 29x in the Pharmaceuticals industry in India. Total returns to shareholders of 26% over the past year.
Valuation Update With 7 Day Price Move • Jun 02Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to ₹101, the stock trades at a trailing P/E ratio of 7.7x. Average trailing P/E is 29x in the Pharmaceuticals industry in India. Total returns to shareholders of 24% over the past year.
분석 기사 • Jun 02Here's Why We Think Quest Laboratories (NSE:QUESTLAB) Is Well Worth WatchingIt's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...
공고 • May 27Quest Laboratories Limited to Report Q4, 2026 Results on May 29, 2026Quest Laboratories Limited announced that they will report Q4, 2026 results on May 29, 2026
New Risk • May 08New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Indian stocks, typically moving 10% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (10% average weekly change). Minor Risk Market cap is less than US$100m (₹2.13b market cap, or US$22.5m).
Valuation Update With 7 Day Price Move • May 01Investor sentiment improves as stock rises 21%After last week's 21% share price gain to ₹152, the stock trades at a trailing P/E ratio of 11.6x. Average trailing P/E is 29x in the Pharmaceuticals industry in India. Total returns to shareholders of 41% over the past year.
Valuation Update With 7 Day Price Move • Apr 17Investor sentiment improves as stock rises 21%After last week's 21% share price gain to ₹127, the stock trades at a trailing P/E ratio of 9.7x. Average trailing P/E is 28x in the Pharmaceuticals industry in India. Total returns to shareholders of 8.5% over the past year.
Valuation Update With 7 Day Price Move • Mar 04Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to ₹110, the stock trades at a trailing P/E ratio of 8.4x. Average trailing P/E is 26x in the Pharmaceuticals industry in India. Total loss to shareholders of 12% over the past year.
Reported Earnings • Feb 16Third quarter 2026 earnings released: EPS: ₹2.46 (vs ₹1.70 in 3Q 2025)Third quarter 2026 results: EPS: ₹2.46 (up from ₹1.70 in 3Q 2025). Revenue: ₹311.8m (up 1.7% from 3Q 2025). Net income: ₹40.3m (up 45% from 3Q 2025). Profit margin: 13% (up from 9.1% in 3Q 2025). The increase in margin was primarily driven by lower expenses.
분석 기사 • Feb 12Does Quest Laboratories (NSE:QUESTLAB) Have A Healthy Balance Sheet?Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...
New Risk • Feb 11New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Indian stocks, typically moving 9.6% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (9.6% average weekly change). High level of non-cash earnings (33% accrual ratio). Minor Risk Market cap is less than US$100m (₹2.12b market cap, or US$23.4m).
Valuation Update With 7 Day Price Move • Feb 11Investor sentiment improves as stock rises 28%After last week's 28% share price gain to ₹129, the stock trades at a trailing P/E ratio of 14.9x. Average trailing P/E is 28x in the Pharmaceuticals industry in India. Total loss to shareholders of 17% over the past year.
공고 • Feb 06Quest Laboratories Limited to Report Q3, 2026 Results on Feb 13, 2026Quest Laboratories Limited announced that they will report Q3, 2026 results on Feb 13, 2026
New Risk • Dec 25New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 6.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (33% accrual ratio). Minor Risks Share price has been volatile over the past 3 months (6.9% average weekly change). Market cap is less than US$100m (₹1.60b market cap, or US$17.8m).
Valuation Update With 7 Day Price Move • Dec 19Investor sentiment improves as stock rises 24%After last week's 24% share price gain to ₹109, the stock trades at a trailing P/E ratio of 12.5x. Average trailing P/E is 28x in the Pharmaceuticals industry in India. Total loss to shareholders of 1.1% over the past year.
분석 기사 • Nov 21Concerns Surrounding Quest Laboratories' (NSE:QUESTLAB) PerformanceQuest Laboratories Limited's ( NSE:QUESTLAB ) healthy profit numbers didn't contain any surprises for investors. We...
공고 • Nov 13Quest Laboratories Limited to Report First Half, 2026 Results on Nov 13, 2025Quest Laboratories Limited announced that they will report first half, 2026 results on Nov 13, 2025
공고 • Sep 04Quest Laboratories Limited, Annual General Meeting, Sep 29, 2025Quest Laboratories Limited, Annual General Meeting, Sep 29, 2025, at 12:30 Indian Standard Time.
Reported Earnings • Jul 26First quarter 2026 earnings released: EPS: ₹2.50 (vs ₹0.90 in 1Q 2025)First quarter 2026 results: EPS: ₹2.50 (up from ₹0.90 in 1Q 2025). Revenue: ₹231.8m (up 52% from 1Q 2025). Net income: ₹41.0m (up 178% from 1Q 2025). Profit margin: 18% (up from 9.7% in 1Q 2025). The increase in margin was driven by higher revenue.
분석 기사 • Jul 26A Piece Of The Puzzle Missing From Quest Laboratories Limited's (NSE:QUESTLAB) 28% Share Price ClimbQuest Laboratories Limited ( NSE:QUESTLAB ) shares have had a really impressive month, gaining 28% after a shaky period...
Valuation Update With 7 Day Price Move • Jul 23Investor sentiment improves as stock rises 16%After last week's 16% share price gain to ₹108, the stock trades at a trailing P/E ratio of 13x. Average trailing P/E is 33x in the Pharmaceuticals industry in India. Total loss to shareholders of 25% over the past year.
New Risk • Jun 30New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Indian stocks, typically moving 9.1% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (9.1% average weekly change). High level of non-cash earnings (29% accrual ratio). Minor Risks Latest financial reports are more than 6 months old (reported September 2024 fiscal period end). Market cap is less than US$100m (₹1.54b market cap, or US$18.0m).
New Risk • Jun 02New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended September 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (29% accrual ratio). Minor Risks Latest financial reports are more than 6 months old (reported September 2024 fiscal period end). Share price has been volatile over the past 3 months (8.5% average weekly change). Market cap is less than US$100m (₹1.43b market cap, or US$16.8m).
New Risk • May 29New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 6.1% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (29% accrual ratio). Minor Risks Share price has been volatile over the past 3 months (6.1% average weekly change). Market cap is less than US$100m (₹1.71b market cap, or US$20.0m).
Valuation Update With 7 Day Price Move • May 29Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to ₹83.75, the stock trades at a trailing P/E ratio of 11.6x. Average trailing P/E is 33x in the Pharmaceuticals industry in India. Total loss to shareholders of 34% over the past year.
Board Change • May 14Less than half of directors are independentThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, 3 were independent directors. The company's board is composed of: 3 independent directors. 4 non-independent directors. Non-Executive Independent Director Gautam Kothari was the last independent director to join the board, commencing their role in 2024. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity.
Valuation Update With 7 Day Price Move • Apr 03Investor sentiment improves as stock rises 17%After last week's 17% share price gain to ₹115, the stock trades at a trailing P/E ratio of 16x. Average trailing P/E is 29x in the Pharmaceuticals industry in India.
Board Change • Mar 06Less than half of directors are independentThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, 3 were independent directors. The company's board is composed of: 3 independent directors. 4 non-independent directors. Non-Executive Independent Director Gautam Kothari was the last independent director to join the board, commencing their role in 2024. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity.
Valuation Update With 7 Day Price Move • Jan 22Investor sentiment improves as stock rises 16%After last week's 16% share price gain to ₹150, the stock trades at a trailing P/E ratio of 20.8x. Average trailing P/E is 33x in the Pharmaceuticals industry in India.
Recent Insider Transactions • Jan 21Chairman & MD recently bought ₹1.2m worth of stockOn the 15th of January, Anil Sabarwal bought around 10k shares on-market at roughly ₹130 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. In the last 3 months, they made an even bigger purchase worth ₹4.2m. Anil has been a buyer over the last 12 months, purchasing a net total of ₹6.7m worth in shares.
Recent Insider Transactions • Jan 07Chairman & MD recently bought ₹4.2m worth of stockOn the 2nd of January, Anil Sabarwal bought around 34k shares on-market at roughly ₹125 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. This was Anil's only on-market trade for the last 12 months.
Valuation Update With 7 Day Price Move • Jan 02Investor sentiment improves as stock rises 17%After last week's 17% share price gain to ₹128, the stock trades at a trailing P/E ratio of 17.8x. Average trailing P/E is 37x in the Pharmaceuticals industry in India.
분석 기사 • Nov 22Quest Laboratories' (NSE:QUESTLAB) Solid Profits Have Weak FundamentalsQuest Laboratories Limited's ( NSE:QUESTLAB ) stock was strong after they recently reported robust earnings. However...
Reported Earnings • Nov 16First half 2025 earnings released: EPS: ₹4.89 (vs ₹4.42 in 1H 2024)First half 2025 results: EPS: ₹4.89 (up from ₹4.42 in 1H 2024). Revenue: ₹434.6m (up 6.0% from 1H 2024). Net income: ₹80.1m (up 46% from 1H 2024). Profit margin: 18% (up from 13% in 1H 2024).
Valuation Update With 7 Day Price Move • Oct 23Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to ₹91.50, the stock trades at a trailing P/E ratio of 14.9x. Average trailing P/E is 38x in the Pharmaceuticals industry in India.
분석 기사 • Oct 22Not Many Are Piling Into Quest Laboratories Limited (NSE:QUESTLAB) Just YetQuest Laboratories Limited's ( NSE:QUESTLAB ) price-to-earnings (or "P/E") ratio of 15.7x might make it look like a...
Board Change • Sep 17Less than half of directors are independentFollowing the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 4 non-independent directors. Non-Executive Independent Director Gautam Kothari was the last independent director to join the board, commencing their role in 2024. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
공고 • Sep 06Quest Laboratories Limited Appoints Executive DirectorsQuest Laboratories Limited at the AGM held on September 4, 2024 approved the regularisation of additional director Mr. Vinayak Sabarwal and Mr. Umendra Singh by appointing them as Executive Directors of the Company.
공고 • Aug 12Quest Laboratories Limited, Annual General Meeting, Sep 04, 2024Quest Laboratories Limited, Annual General Meeting, Sep 04, 2024, at 16:30 Indian Standard Time.
Valuation Update With 7 Day Price Move • Jun 11Investor sentiment improves as stock rises 18%After last week's 18% share price gain to ₹128, the stock trades at a trailing P/E ratio of 41.6x. Average trailing P/E is 33x in the Pharmaceuticals industry in India.